The case for primary prevention of obesity in the era of GLP-1 therapies
{{output}}
Obesity rates continue to rise across Europe, driven by obesogenic environments shaped by food systems, urban design, socioeconomic inequalities, and commercial forces. The introduction of incretin-based pharmacotherapies like GLP-1 receptor agonists has trans... ...
